Explore Your Topic
Inform Yourself on Special Topics
Latest News
Share Price / Index
September 10, 2024
Not intended for UK Media – Late-breaking data from Phase III long-term study OASIS 3 presented at 2024 TMS Annual Meeting:
Data from Phase III study OASIS 3 support efficacy and long-term safety of investigational compound elinzanetant in the treatment of moderate to severe vasomotor symptoms associated with menopause
September 10, 2024
Not intended for U.S. and UK Media – Late-breaking data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024
New subgroup analysis from FINEARTS-HF revealed patients with heart failure and a left ventricular ejection fraction of ≥40% receiving finerenone had a reduced risk of new-onset diabetes
September 01, 2024
Not intended for U.S. and UK - Media Late-Breaking data from pivotal Phase III FINEARTS-HF study presented at ESC Congress 2024
Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure with high unmet medical need
Advance Your Career
Explore Our Businesses
We address some of the world's most pressing global challenges and continue to develop new solutions. The population is constantly growing and its age is increasing. That is why it needs better medicines and high-quality food in sufficient quantities. Learn more about it here.
Find Your Product
With our products we contribute to the health of people and plants. Here you find an overview of the major Bayer products.
A
Z
products/products-z